SCHEMBL336256

SCHEMBL336256

CSc1ccccc1N1CCNCC1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 18/20 0.66
HTR3A P46098 18/20 0.66
CYP1A2 P05177 10/20 0.62
CYP3A4 P08684 10/20 0.62
CYP2D6 P10635 10/20 0.62
CYP2C9 P11712 10/20 0.62
ADRB1 P08588 4/20 0.59
ADRB2 P07550 2/20 0.57
HRH2 P25021 2/20 0.57
HTR1B P28222 2/20 0.57
HTR2A P28223 2/20 0.57
HTR2C P28335 2/20 0.57
SLC6A4 P31645 2/20 0.57
HTR7 P34969 2/20 0.57
HRH1 P35367 2/20 0.57
HTR5A P47898 2/20 0.57
HTR6 P50406 2/20 0.57
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19888716 0.84 HTT (0.51) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL546723 0.84 HTR1A (0.78) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL2783783 0.83 HTR1A (0.51) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL30100764 0.82 GAA (0.48) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL9024968 0.82 GAA (0.48) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL27629618 0.82 HTR1A (0.57) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL11603387 0.81 HTR1A (0.60) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL17109939 0.80 HTR1A (1.00) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
SCHEMBL29393390 0.80 HTR1A (1.00) HTR1AHTR3ACYP1A2CYP3A4CYP2D6
Bromide SCHEMBL11179225 0.80 HTR1A (0.59) HTR1AHTR3ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery UNIV JOHNS HOPKINS (US) 2026-04-02 US disclosed
US-12527746-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2026-01-20 US disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 US disclosed
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery THE JOHNS HOPKINS UNIVERSITY (US) 2025-07-29 US disclosed
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS THE JOHNS HOPKINS UNIVERSITY 2025-05-01 US disclosed
US-20240263196-A1 Lipid Compositions and Methods for Delivery to Immune Cells Life Technologies Corporation 2024-08-08 US disclosed
US-12049530-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERISTY (US) 2024-07-30 US disclosed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
CN-1152916-A Trifluoromethylquinoline carboxylic acid derivative UBE INDUSTRIES (JP) 1997-06-25 CN disclosed
EP-0773214-A1 TRIFLUOROMETHYLQUINOLINECARBOXYLIC ACID DERIVATIVE UBE INDUSTRIES, LTD. (JP) 1997-05-14 EP disclosed
EP-0711757-A1 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists F. Hoffmann-La Roche AG (CH) 1996-05-15 EP disclosed
WO-1996002510-A1 NOVEL 1-[4(AMINO METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS BAYER AKTIENGESELLSCHAFT (DE) 1996-02-01 WO disclosed
EP-0322643-B1 MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE BAYER AG (DE) 1991-07-24 EP disclosed
US-4940705-A VIRICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-07-10 US disclosed
EP-0322643-A1 Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use BAYER AG (DE) 1989-07-05 EP disclosed
EP-0313974-A1 N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals BAYER AG (DE) 1989-05-03 EP disclosed
US-3947446-A HYPOTENSIVE BOEHRINGER MANNHEIM GMBH (DT) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527746-B2 Peptide/particle delivery systems VEGFA, IGF2BP2, MSTN HTR1A 1346/4885HTR3A 2147/4885CYP1A2 4840/4885
US-20250136737-A1 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS PEF1, FIBP, PARN HTR1A 2004/4885HTR3A 1018/4885CYP1A2 4815/4885
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 HTR1A 2495/4885HTR3A 2204/4885CYP1A2 4635/4885
US-12371522-B2 Bioreducible poly (beta-amino ester)s for siRNA delivery AARS1, SLC43A1, PHAX HTR1A 4516/4885HTR3A 4002/4885CYP1A2 4850/4885
US-12049530-B2 Multicomponent degradable cationic polymers PEF1, FIBP, PARN HTR1A 2004/4885HTR3A 1018/4885CYP1A2 4815/4885
US-20260092134-A1 Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery SLC43A1, SLC7A5, SLC7A1 HTR1A 4712/4885HTR3A 4257/4885CYP1A2 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.